Court blocks switch to rebate model for safety‑net 340B drug discounts

A federal district judge and an appeals court have halted the Trump administration’s planned 340B Rebate Pilot Program, preventing the Health Resources and Services Administration from requiring safety-net hospitals and other covered entities to pay full price at the point of sale and recover savings later through post-sale rebates. The pilot was due to take effect Jan. 1, 2026.

U.S. District Judge Lance E. Walker of the District of Maine issued a preliminary injunction on Dec. 29, 2025, finding the program likely violated the Administrative Procedure Act. Judge Walker concluded that HRSA had not adequately assessed the pilot’s impacts on 340B covered entities and described the agency’s administrative record as insufficient. The court also questioned HRSA’s plan to continue soliciting stakeholder input while moving forward with implementation.

The Department of Health and Human Services appealed immediately and sought emergency relief from the U.S. Court of Appeals for the First Circuit. The appeals panel declined to lift the injunction on Dec. 31, 2025, and ordered an expedited briefing schedule, signaling it will resolve the broader stay request as soon as practicable. In the interim HRSA posted a notice pausing implementation as of noon on Dec. 31, and manufacturers are to continue providing upfront 340B discounts while the litigation and administrative procedures play out.

The pilot would have altered a decades-old mechanism that requires drug manufacturers to offer discounted prices to eligible hospitals, clinics and health centers that serve large shares of uninsured and low-income patients. Regulators supporting the pilot argued the policy was intended to curb inappropriate discounts where drugs are not properly within the 340B program’s scope as the program has grown. Hospital groups countered that the agency rushed implementation without adequate stakeholder consideration and without explaining how the change would affect patient care and provider finances.

Plaintiffs in the challenge included the American Hospital Association, the Maine Hospital Association and four health systems that sued HRSA on Dec. 1, 2025. They argued the change would disrupt the cash flow safety‑net providers rely on to underwrite pharmacy assistance programs, subsidize outpatient services and sustain care in rural and underserved urban communities.

Legal rulings to date focus on procedural defects in HRSA’s rulemaking rather than a final judgment on the merits of the underlying policy. If the appeals court ultimately upholds the injunction, HRSA would need to return to rulemaking with a fuller administrative record demonstrating careful consideration of the pilot’s effects. If the agency prevails on appeal and the pilot proceeds, hospitals and community health programs face a rapid operational transition that could imperil patient access to medications and ancillary services.

Advocacy groups for hospitals have hailed the court decisions as a temporary reprieve for 340B providers. For patients, pharmacists and clinic directors who manage limited resources, the rulings preserve the current, predictable flow of discounts that helps finance care for people with low incomes and no insurance. The case now moves through the First Circuit on an accelerated timeline, and its outcome will shape both the future of federal drug pricing policy and the fiscal stability of institutions that form the backbone of the nation’s safety-net health system.